By Connor Hart
Exicure has inked two equity-financing deals, receiving $10 million in exchange for a controlling interest in the company.
The Chicago biotechnology company will receive $1.3 million from HiTron Systems, a South Korean security-systems provider, for 433,333 shares of its common stock. Upon the deal's closing, HiTron will have the right to appoint two nominees to the Exicure's board, subject to certain conditions, it said Thursday.
Separately, Exicure will sell an additional 2.9 million shares of its common stock to HiTron, also for $3 apiece, or $8.7 million. Upon closing of this subsequent investment, HiTron will have the right to appoint additional nominees in proportion to its equity interest.
Shares edged 1.3% lower, to $3.14, in after-hours trading.
The company, which previously received an extension to show compliance with all applicable listing criteria by Nov. 14, believes it will meet these requirements following its equity-financing deals.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 14, 2024 18:13 ET (23:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.